ABT 888 enters Phase III trial for Breast Cancer-AbbVie

AbbVie has initiated a Phase III clinical trial evaluating the safety and efficacy of ABT 888 (veliparib) when added to carboplatin in women with early-stage, triple-negative Breast Cancer. The three-arm trial will compare the addition of veliparib plus carboplatin or placebo plus carboplatin to standard neoadjuvant chemotherapy.

The randomized, placebo-controlled, double-blind trial will recruit approximately 620 patients who will be randomized to one of three arms of the trial. The primary efficacy outcome of the trial is pathological complete response, which is achieved when there is no evidence of residual, invasive cancer in the breast tissue and lymph node tissue, following treatment. The secondary outcome of the trial will determine the rate of eligibility for breast conservation after therapy.